459 related articles for article (PubMed ID: 18959605)
1. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
2. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
3. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
4. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
5. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
Dailey G; Strange P
Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
[TBL] [Abstract][Full Text] [Related]
6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
7. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
Home PD; Fritsche A; Schinzel S; Massi-Benedetti M
Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
10. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
11. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
12. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
[TBL] [Abstract][Full Text] [Related]
15. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
Yki-Järvinen H
Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
Rosak C; Jung R; Hofmann U
Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
18. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
20. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
De Mattia G; Laurenti O; Moretti A
Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]